Batavia and ChromaTan receive NIIMBL grant to integrate column-free continuous chromatography into HIP-Vax® manufacturing platform for AAV 

Batavia and ChromaTan receive NIIMBL grant to integrate column-free continuous chromatography into HIP-Vax® manufacturing platform for AAV 

Woburn, MA, April 10, 2024 — Batavia Biosciences, a leading contract development and manufacturing organization, is excited to announce a new alliance with ChromaTan, Inc.  for the development and integration of BioRMB™ (formerly known as Continuous Countercurrent Tangential Chromatography or CCTC) technology into Batavia’s AAV HIP-Vax® manufacturing platform. This project further highlights Batavia’s commitment to improve AAV manufacturing, while reducing manufacturing costs and optimize the environmental footprint of biopharmaceuticals through process intensification.

Recombinant adeno-associated virus (rAAV) vectors are spearheading the development of next generation treatments to cure debilitating and life-threatening disorders. However, demand for rAAV is exceeding its production capacity, threatening to become a bottleneck in the treatment of large patient groups.

Continuous chromatography has been shown to greatly contribute to the intensification of manufacturing processes for monoclonal antibodies. Yet, similar applications for rAAV are still lacking. As a leading CDMO, Batavia Biosciences expects to increase its rAAV production capacity and to further reduce the associated cost of goods through integration of ChromaTan’s BioRMBTM – a novel column-free real moving bed continuous chromatography platform – into Batavia’s proprietary HIP-Vax® manufacturing platform.

“The promise of next generation platforms both upstream and downstream in the field of gene therapy is very powerful for multiple reasons such as improvements in manufacturability, process economics, improved recovery and product quality. This exciting partnership enabled by NIIMBL, will empower us to take that idea a step further – by directly integrating these hyper efficient next generation platforms we have the potential to transform rAAV manufacturing as we know it” says Oleg Shinkazh, Chief Technical officer at Chromatan.

Peter Abbink, Managing Director at Batavia Biosciences, Inc., adds: “At Batavia, we continuously seek innovative solutions to fuel our mission to enhance the accessibility and availability of critical life-changing treatments. We are privileged to have the backing of NIIMBL and are thrilled to embark on a productive partnership with ChromaTan on this endeavor.”

This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology (70NANB21H086).

Batavia partners in consortium to develop vaccine against Rift Valley fever 

Batavia partners in consortium to develop vaccine against Rift Valley fever 

Batavia Biosciences is proud to be a key partner in an important initiative aimed at combating the deadly Rift Valley fever. We are thrilled to share that as part of the consortium working alongside esteemed partners such as Wageningen Bioveterinary Research, Bunyavax BV, CR2O BV, University of Veterinary Medicine Hannover, and Integrum Scientific, LLC, we are stepping up our efforts to bring a protective vaccine to East Africa, where Rift Valley fever is endemic.

Batavia’s role as consortium partner

Our role in this endeavor is pivotal. At Batavia, we strive to reduce human suffering from infectious disease by helping improve vaccine affordability and availability around the world. Therefore, we have specialized in developing highly intensified manufacturing processes, leveraging our cutting-edge HIP-Vax® platform to create vaccines with a low cost of goods. As a consortium partner, our primary focus is on developing a scalable manufacturing process that can be rapidly scaled-up in the event of an outbreak. Furthermore, we are honored to take on the responsibility of manufacturing the clinical material for the Phase I and IIa trials planned for East Africa.

This initiative is a significant milestone in our ongoing battle against infectious diseases, particularly Rift Valley fever. The project, generously supported with up to US$25.9 million in funding from CEPI and backed by the European Union’s Horizon Europe program, will accelerate the development of a much-needed protective vaccine in East Africa.

Rift Valley fever: A climate-driven disease with epidemic potential

Rift Valley fever is a potentially lethal virus that can be transmitted to humans through mosquito bites or contact with infected livestock. With climate change increasing the risk of RVF outbreaks, the need for a protective human vaccine has never been more urgent. As a ‘One Health’ priority, the development of safe and effective human vaccines for RVF is crucial, and we are committed to playing our part in this vital endeavor.

Together with our esteemed partners and the support of CEPI and the European Union, we are determined to make a difference in the fight against Rift Valley fever.

Read the full press release for more details: CEPI expands partnership with Wageningen Bioveterinary Research to advance clinical trials of Rift Valley fever vaccine in affected countries – CEPI

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression